Bill Detail

H.R. 1117

Congress: 119

Title

Responsibility in Drug Advertising Act of 2025

Summary

Responsibility in Drug Advertising Act of 2025 This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. The prohibition applies to new drugs approved beginning one year before the bill’s enactment.

Sponsor

Rep. Rosa DeLauro [D-CT-3]

Status

Referred to the House Committee on Energy and Commerce.

Status as of Nov 13, 2026, 8:04 AM · synced 3d ago

Introduced

2025-02-07

Data source mode: congress-gov

Bill Engagement

Lobbyists on the case

1 org · 12 lobbyists · 1 filing mention H.R. 1117 (Responsibility in Drug Advertising Act of 2025) in LDA disclosures.

These are cached disclosure mentions, not verified current representation or confirmed event attendance.

Top orgs filing
Lobbyists on this bill
+ 10 more in the full intelligence view

Limited preview · paid intelligence

Keep the intelligence current—not just this one record.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.

SEE A FINISHED HEALTHCARE EXAMPLE

Three days of Hill visits. Two Medicare access questions.

A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.

Read the finished healthcare brief →
Buy Federal Intelligence · $2,500 for 3 monthsPrefer a walkthrough first?Already a customer? Sign inGet free intelligence alerts →

After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.